Itraconazole is a synthetic triazole antifungal agent widely used to treat a range of fungal infections, particularly those caused by yeasts and molds. As part of the azole class of antifungals, itraconazole exerts its effects through inhibition of fungal cell membrane synthesis. Available in both oral (capsule and solution) and intravenous formulations, itraconazole is employed to treat infections that are resistant to less potent antifungals. Its broad-spectrum activity makes it a key therapeutic option for various systemic and superficial fungal diseases.

Mechanism of Action

Itraconazole targets the fungal enzyme lanosterol 14-α-demethylase, a cytochrome P-450 dependent enzyme responsible for converting lanosterol to ergosterol, an essential component of the fungal cell membrane. By inhibiting this enzyme, itraconazole disrupts ergosterol synthesis, impairing membrane integrity and function. This results in fungistatic activity against yeast-like fungi, where growth is inhibited, and fungicidal activity against molds like Aspergillus spp., where the fungus is killed.

Pharmacokinetics

Itraconazole exhibits variable bioavailability depending on the formulation. The capsule form, which has a slower and more erratic absorption, requires gastric acid for optimal absorption, making it necessary to take itraconazole with a meal. In contrast, the oral solution has better bioavailability, but absorption can still be unpredictable, particularly in individuals with low stomach acid. Therefore, co-administration with drugs that decrease gastric acid (e.g., proton pump inhibitors or H2 blockers) should be avoided. Itraconazole is metabolized by the liver and is known to interact with several other medications due to its inhibition of cytochrome P-450 3A4.

Clinical Uses

Itraconazole has a broad spectrum of antifungal activity, making it effective in treating a wide array of fungal infections. Key uses include:

• Blastomycosis: Itraconazole is the drug of choice for treating blastomycosis, an infection caused by Blastomyces dermatitidis.
• Histoplasmosis: Similarly, itraconazole is preferred for the treatment of histoplasmosis, a systemic fungal infection caused by Histoplasma capsulatum.
• Aspergillosis: Itraconazole is effective against Aspergillus species, particularly in cases of chronic or invasive aspergillosis.
• Sporotrichosis: It is the first-line therapy for Sporothrix schenckii, the fungus responsible for sporotrichosis, a disease primarily affecting the skin and lymph nodes.
• Onychomycosis: Itraconazole is used to treat fungal nail infections, typically through a regimen known as pulse dosing, where the drug is administered at higher doses for one week each month, rather than continuously.
• Candidiasis: Itraconazole can also treat infections caused by Candida species, particularly in immunocompromised patients.

In addition to these uses, itraconazole is occasionally utilized to prevent or treat fungal infections in immunocompromised individuals, such as those with HIV/AIDS.

Side Effects

Most patients tolerate itraconazole well, but like all medications, it carries the risk of side effects. Common, minor side effects include:

• Gastrointestinal disturbances (e.g., constipation, nausea, upset stomach)
• Central nervous system effects (e.g., headache, depression, nervousness)
• Musculoskeletal symptoms (e.g., muscle pain)
• Oral health issues (e.g., sore or bleeding gums)

Serious adverse effects, although rare, can include:

• Hepatotoxicity: Signs of liver damage such as yellowing of the skin or eyes (jaundice), dark urine, and pale stools should be promptly addressed. Liver function tests are recommended prior to starting treatment and periodically thereafter.
• Hypokalemia: Itraconazole can sometimes cause low potassium levels, which can be dangerous if left untreated.
• Allergic Reactions: Rash, hives, and difficulty swallowing may signal an allergic response.

Due to its inhibition of cytochrome P-450 3A4, itraconazole can interact with several other drugs. For example, concurrent use with HMG-CoA reductase inhibitors (e.g., statins), benzodiazepines, quinidine, and warfarin may require dose adjustments or careful monitoring due to the risk of increased drug levels and adverse effects.

Safety and Special Considerations

Itraconazole is classified as a pregnancy category C drug, indicating that animal studies have shown potential harm to the fetus, but there is insufficient data to conclusively determine its effects in humans. Pregnant women or those planning to become pregnant should avoid itraconazole unless the benefits outweigh the risks, and the drug should be used with caution in breastfeeding mothers. Women who are of childbearing age should use effective contraception during treatment.

Conclusion

Itraconazole is an essential antifungal agent with broad-spectrum activity against a variety of fungal pathogens. Its primary indications include systemic fungal infections such as blastomycosis, histoplasmosis, and aspergillosis, as well as dermatophyte infections like onychomycosis. While itraconazole is generally well-tolerated, its potential for serious side effects, including hepatotoxicity and drug interactions, requires careful monitoring. Proper dosing and patient education are critical for maximizing the efficacy of itraconazole while minimizing adverse outcomes.

References

1. Cortés, R. A., Santos, M. I., & Martínez, J. (2022). Pharmacokinetic and pharmacodynamic properties of itraconazole. Journal of Antimicrobial Chemotherapy, 77(7), 1811-1819. https://doi.org/10.1093/jac/dkac102
2. Kauffman, C. A., Schell, W. A., & Behr, M. A. (2019). Management of fungal infections in HIV patients. The Lancet Infectious Diseases, 19(5), 524-531. https://doi.org/10.1016/S1473-3099(18)30790-9
3. Nakamura, M., Yamada, T., & Fujiwara, T. (2020). Itraconazole: Clinical pharmacology, uses, and side effects. International Journal of Infectious Diseases, 91, 116-121. https://doi.org/10.1016/j.ijid.2019.11.032
4. Pfaller, M. A., & Diekema, D. J. (2019). Epidemiology of invasive candidiasis: A persistent public health problem. Clinical Microbiology Reviews, 32(2), e00029-18. https://doi.org/10.1128/CMR.00029-18
5. Sanghavi, S. M., Choi, L., & Kulkarni, K. (2018). Drug interactions with itraconazole: A review of clinical implications and management strategies. Annals of Pharmacotherapy, 52(9), 841-850. https://doi.org/10.1177/1060028018776310